long-term treatment [hlca]
pitavastatin [orch, phsu]
NK 104 [orch, phsu]
HMG CoA Reductase [aapp, enzy]
Inhibitor [qlco]
Patients [podg]
Heterozygous [orga]
Familial hypercholesterolaemia [dsyn]
Efficacy [qlco]
Safety [hcpp]
pitavastatin [orch, phsu]
NK 104 [orch, phsu]
Novel [tmco]
HMG-CoA reductase inhibitor [orch, phsu]
long-term treatment [hlca]
Examined [fndg]
Patients [podg]
Female [fndg]
Age [orga]
SD [fndg]
Heterozygous [orga]
Familial hypercholesterolaemia [dsyn]
placebo [topp]
4 Weeks [tmco]
mg day [qnco]
pitavastatin [orch, phsu]
Administered [ftcn]
weeks [tmco]
Dose [qnco]
Increased [qnco]
mg day [qnco]
weeks [tmco]
Total Cholesterol [lbpr]
Decreased [qnco]
Initial [tmco]
Value [qnco]
mg dl [qnco]
P NOS [aapp, imft]
treatment [ftcn]
High dose [qnco]
Total Cholesterol [lbpr]
Decreased [qnco]
mg dl [qnco]
Decreased [qnco]
Initial [tmco]
Value [qnco]
P NOS [aapp, imft]
baseline [bodm]
Low density lipoprotein [aapp, bacs, lipd]
LDLC [gngm]
Decreased [qnco]
mg dl [qnco]
baseline [bodm]
findings [ftcn]
Dose-dependent [qnco]
Drug [phsu]
Total Cholesterol [lbpr]
Concentrations [menp]
Levels [qlco]
Circulating [ftcn]
Matrix Metalloproteinases [aapp, enzy]
Endogenous [ftcn]
inhibitors [chvf]
Tissue [tisu]
inhibitors [chvf]
Metalloproteinases [aapp, enzy]
Altered [ftcn]
Lipid-lowering therapy [topp]
Measured [qlco]
Plasma [bdsu]
Levels [qlco]
MMP-2 [aapp, enzy]
Increased [qnco]
Alteration [idcn]
MMP-9 [aapp, enzy]
TIMP-1 [aapp, bacs]
2 levels [inpr]
Safety [hcpp]
pitavastatin [orch, phsu]
Adverse reactions [fndg]
Observed [ftcn]
Subjective [qlco]
Objective [inpr]
symptoms [ftcn]
effects [qlco]
pitavastatin [orch, phsu]
Total Cholesterol [lbpr]
Stable [qlco]
Long [qlco]
treatment [ftcn]
Patients [podg]
Heterozygous [orga]
Familial hypercholesterolaemia [dsyn]
Science [ocdi]
Ireland [geoa]
LTD [ortf]
Reserve [acty]
